ATLAS News · Companies

SELLAS Life Sciences Proposes $150 Million Stock Offering After Phase 3 REGAL Data

· 6 sources

SELLAS Life Sciences (SLS) plans a $150 million public offering after its Phase 3 REGAL trial met its survival goal, according to several outlets.

What happened

SELLAS Life Sciences (NASDAQ: SLS) announced a proposed underwritten public offering of common stock worth $150 million, according to Investing.com, MarketScreener, The Manila Times and TokenPost. The announcement followed results from the company's Phase 3 REGAL trial.

Kalkine reports that the trial reached its survival goal, and that the shares surged during the session. Stock Titan notes survival figures of 24 months versus 14.7 months in the trial.

Stock Titan adds that the underwriters have a 30-day option to buy up to $22.5 million of additional stock. The expected proceeds are earmarked for uses that include clinical development and potential commercialization.

Context

Companies in clinical-stage biotechnology often raise capital through public offerings after reporting trial results, which can increase the number of shares outstanding.

Why it matters

The offering shows how SELLAS plans to fund its next steps after the trial data, and it may affect the company's share count and financing position.

Stocks in this story

Price changes are shown for the trading day of the story and are a coincidence in time, not proof that the news caused them. Figures are ATLAS data from our database.

Closing prices, fair value and probabilities: ATLAS own data. How we calculate fair value.

Sources

ATLAS writes its own summaries from the reporting of these outlets. Each link opens the original publisher.

  1. SELLAS Life Sciences (NASDAQ:SLS) Soars 166% in Today's Session After Phase 3 REGAL Trial Hits Survival Goal · kalkine.ca · November 17, 2026
  2. A proposed stock offering at SELLAS (SLS) comes with Phase 3 survival of 24 vs. 14.7 months. · Stock Titan · November 17, 2026
  3. SELLAS Life Sciences launches $150 million stock offering By Investing.com · Investing.com Canada · November 17, 2026
  4. SELLAS Life Sciences Group Begins $150 Million Stock Offering · www.tokenpost.com · November 17, 2026
  5. SELLAS Life Sciences Plans $150 Million Public Offering of Common Stock · marketscreener.com · November 17, 2026
  6. SELLAS Life Sciences Announces Proposed $150.0 Million Underwritten Public Offering · The Manila Times · November 17, 2026

Related

Latest market news · Markets today on ATLAS · SELLAS Life Sciences Group

What you get with ATLAS

Create my ATLAS account →

Fair value, probabilities and earnings for every stock. Free account, no card. Information, not advice.

Information, not advice. This content is informational and is not an investment recommendation or an offer to buy or sell securities. ATLAS estimates come from statistical models using public data, can be wrong, and past performance does not guarantee future results. Disclaimer

ATLAS Signals

ATLAS Signals, every week

The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.

By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy